Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $14.00 to $12.00. They now have a "buy" rating on the stock.
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.